Medical Affairs Department, Merck Serono S.p.A., Rome, Italy.
SSD di Endocrinologia Pediatrica e, Centro Screening Neonatale, Ospedale Pediatrico Miccrocitemico "A. Cao", AO Brotzu, Via Jenner, 09121, Cagliari, Italy.
J Endocrinol Invest. 2019 Oct;42(10):1241-1244. doi: 10.1007/s40618-019-01046-1. Epub 2019 Apr 9.
With the use of non-objective measurement, adherence to growth hormone (GH) therapy has been reported suboptimal in a large proportion of patients, and poor adherence has been shown to affect short-term growth response in patients receiving GH treatment.
The Easypod™ electronic device allows objective measurement of adherence. In this study, we report 3-year prospective adherence data of the Italian cohort of naïve GH deficient (GHD) children extrapolated from the Easypod Connect Observational Study (ECOS) database.
Seventy-three GHD children naïve to GH treatment were included in the analysis. 22 Italian centers participated in the study.
Mean adherence rate was consistently above 85% across the 3-year observation period. Particularly, mean adherence was 88.5%, 86.6%, and 85.7% after 1, 2 and 3 years, respectively. Mean (± SD) height-SDS increase after the first year was 0.41 (± 0.38).
The majority of naïve GHD children starting GH treatment with Easypod maintained an adherence rate > 85% up to 3 years. Easypod is a useful tool to follow-up patients' adherence allowing timely intervention to improve optimal treatment for these patients.
由于使用非客观测量方法，很大一部分患者的生长激素（GH）治疗依从性被报告为不理想，并且已经证明，治疗依从性差会影响接受 GH 治疗的患者的短期生长反应。
Easypod™电子设备可进行客观的治疗依从性测量。在这项研究中，我们报告了从 Easypod Connect 观察性研究（ECOS）数据库中推断出的意大利初治 GH 缺乏症（GHD）儿童的 3 年前瞻性依从性数据。
共有 73 名初治 GH 治疗的 GHD 儿童纳入分析。22 个意大利中心参与了这项研究。
在 3 年的观察期间，平均依从率始终保持在 85%以上。特别是，第 1、2 和 3 年的平均依从率分别为 88.5%、86.6%和 85.7%。第一年身高 SDS 的平均（±标准差）增加量为 0.41（±0.38）。
大多数开始使用 Easypod 进行 GH 治疗的初治 GHD 儿童在 3 年内保持了超过 85%的依从率。Easypod 是一种有用的工具，可以监测患者的依从性，及时进行干预，以改善这些患者的最佳治疗效果。
